The gap.
Biology moves faster than the infrastructure designed to carry it. Accenture's February 2026 study traces 64% of launch delays to chemistry, manufacturing and controls. The principals who own that gap meet at BILS.
01
Every biologics leader is asked the same question. How a molecule becomes supply at scale. The platform between candidate and patient is being rebuilt.
02
Closed door. By invitation. Led by end users. A circle for the leaders who take a process from first batch to full supply.
03
the Conversation. BILS is that room. Senior biologics leadership convened around the plant, from cell line to release. Process. Transfer. Supply.
04
Who attends. Senior faculty drawn from the leaders who own the plant, sign the batch and carry the accountability.
the Why
Who manufactures
the future.
The leadership the next plant is built around.
The gap.
Biology moves faster than infrastructure. Every plant is asked to scale. The process decides which ones do. Governance turns a facility into a platform. Scale turns a pilot into supply. Judgement turns supply into medicine.
the Circle.
BILS convenes the leaders who hold that role across upstream, downstream, contract manufacturing and the digital plant. Here the AI strategy conversation opens, at the plant, where accountability is already law. It continues in London in May.
The decision.
What scales. Capacity now follows policy, and Europe must decide where it builds while American tariffs and its own Critical Medicines Act pull in different directions. What purifies. Downstream decides yield, cost and release, and Europe is writing the rule for AI in GMP. Who manufactures the future. A model may draft the record. Only the quality unit can clear it.
From bioreactor to release.
By invitation. By relevance. By room.
Attend BILS 2027